Harvard Bioscience Introduces Next Generation Inhalation System to Aid in the Fight Against COVID-19
24 March 2020 - 12:00AM
Harvard Bioscience, Inc. (Nasdaq: HBIO) has launched an innovative
technology – known as Accumulated Inhaled Aerosol (AIA) – for
academic researchers, contract research organizations (CROs) and
pharmaceutical companies involved in pre-clinical inhalation and
exposure studies. With our new Buxco® AIA system, researchers are
presented with real-time aerosol amounts inhaled and deposited in
subjects’ lungs, a breakthrough improvement over the current
delivered dose measurement. By reporting those measures against
real-time respiratory endpoints using FinePointe software,
researchers can now observe a direct correlation between dose and
lung function over time.
“Researchers worldwide are focused on finding a treatment to
COVID-19, and we are proud to provide advanced instrumentation to
contribute to this effort,” said Jim Green, President and CEO of
Harvard Bioscience. “This is a transformational technology that
gives our customers the ability to know the delivered dose and the
resulting lung function, all on an easy-to-use software
platform.”
Integrating exposure and respiratory capabilities, this system
delivers precise amounts of various aerosols to multiple subjects
in a uniform, and reproducible manner, then measures pulmonary
effects from the same platform. This technology and other new
advancements in the Harvard Bioscience inhalation platform provide
researchers with novel tools to study COVID-19 and advance
development in both the discovery of new therapies and the
pre-clinical regulatory phases, as solutions progress toward
general clinical use.
Green added, “We are seeing immediate interest in our Buxco® AIA
system from CROs and pharmaceutical companies in China and around
the world, and expect academic research demand to increase as
researchers return to their labs. Notably, in spite of COVID-19’s
impact on markets and world-wide supply chains, Harvard Bioscience
is fortunate to continue to be in a position during this crisis to
develop, manufacture and ship game-changing new products for
research and drug development around the world.”
About Harvard Bioscience
Harvard Bioscience is a leading developer, manufacturer and
seller of technologies, products and services that enable
fundamental research, discovery, and pre-clinical testing for drug
development. Our customers range from renowned academic
institutions and government laboratories, to the world’s leading
pharmaceutical, biotechnology and contract research organizations.
With operations in North America and Europe, we sell through a
combination of direct and distribution channels to customers around
the world.
For more information, please visit our website at
www.harvardbioscience.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws, including the Private
Securities Litigation Reform Act of 1995. You can identify these
statements by our use of such words as "will," “contribute,”
“provide,” "continue," “advance,” and similar expressions that do
not relate to historical matters. Forward-looking statements in
this press release may include, but are not limited to, statements
or inferences about the Company's or management's beliefs or
expectations as to the Company's ability to continue to develop,
manufacture and ship products, interest in the Company’s products,
and success of the company’s products in enhancing efforts as to
study and development treatments with respect to COVID-19. These
statements involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Investors should note that many
factors, as more fully described under the caption “Risk Factors”
in our Form 10-K, including our Form 10-K for the year ended
December 31, 2019, and subsequent filings made by the Company with
the Securities and Exchange Commission and as otherwise enumerated
herein or therein may cause the Company's actual results to differ
materially from those in the forward-looking statements. The
forward-looking statements in this press release are qualified by
these risk factors. The Company's results may also be affected by
factors of which the Company is not currently aware. The Company
may not update these forward-looking statements, even though its
situation may change in the future, unless it has obligations under
the federal securities laws to update and disclose material
developments related to previously disclosed information.
For investor inquiries, please contact Michael A. Rossi, Chief
Financial Officer at (508) 893-8999.
Press releases may be found on the Harvard Bioscience
website.
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024